|

CAR-T Clinical Trials

8 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Pipeline

Phase 1: 3Phase 2: 1Phase 3: 2Phase 1/2: 1

Top Sponsors

  • The Third Affiliated Hospital of Southern Medical University1
  • Peking University People's Hospital1
  • Memorial Sloan Kettering Cancer Center1
  • Institute of Hematology & Blood Diseases Hospital, China1
  • Hong Kong Children's Hospital1

Indications

  • Cancer8
  • Multiple Myeloma2
  • MRD-positive1
  • Allogenetic Hematopoietic Stem Cell Transplantation1
  • Non-Hodgkin Lymphoma (NHL)1

Other6 trials

CAR-T in Relapsed/Refractory Multiple Myeloma
Phase 2
CD-19 CAR-T Cell for Pediatric ALL or Lymphoma
N/A
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
Phase 1
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Phase 1/2
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
Phase 1

New York, New York1 trial

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Memorial Sloan Kettering Cancer Center

Phase 3

Philadelphia, Pennsylvania1 trial

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

Abramson Cancer Center, University of Pennsylvania

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.